Positive Opinions, Solid Margins, Agreements, and Clinical Trials to Boost Run Rate of Drug Manufacturers - Research Report on Johnson & Johnson, Pfizer, Merck, Bristol-Myers Squibb, and Lilly

NEW YORK, August 6, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY), and Eli Lilly, and Company (NYSE: LLY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On July 26, 2013, Johnson & Johnson announced that its pharmaceutical business arm, Janssen-Cilag International NV (Janssen), has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), for the use of STELARA (ustekinumab). According to the Company, CHMP recommends the use of STELARA (ustekinumab), alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. Jerome A. Boscia, M.D., Vice President, Head of Immunology Development, Janssen Research & Development, LLC, said, "Data from the Phase 3 clinical program, one of the largest conducted for a biologic to date in psoriatic arthritis, showed STELARA effective in improving symptoms and signs of active psoriatic arthritis in anti-tumor necrosis factor (TNF)-alpha naïve and experienced patients. We believe STELARA has the potential to play a critically important role in the treatment of this chronic disease and look forward to the European Commission's decision." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-02/JNJ]

--

Pfizer Inc. Research Report

On July 30, 2013, Pfizer Inc. (Pfizer) released its Q2 2013 financial results. The Company's revenues were down 7.1% YoY to $13.0 billion in Q2 2013. Net income was $14.1 billion or $1.98 per diluted share in Q2 2013, compared to net income of $3.3 billion or $0.43 per diluted share in Q2 2012. Ian Read, Chairman and CEO of Pfizer, stated, "I am pleased with our recent accomplishments focused on creating greater value for our shareholders, including the completion of the full disposition of Zoetis which generated over $17 billion in value as well as the announcement of our new commercial model. This new model represents the next step in Pfizer's journey to further revitalize our innovative core, enhance the value of our consumer and off-patent established brands and maximize the use of our capital to create value for Pfizer and our patients, consumers and shareholders." The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-02/PFE]

--

Merck & Co. Inc. Research Report

On July 30, 2013, Merck & Co. Inc. (Merck) released its Q2 2013 financial results. The Company's sales were down 10.6% YoY to $11.0 billion, during the quarter. Net income attributable to the Company was down 49.5% YoY to $906 million, and diluted EPS was down 48.3% YoY to $0.30, in Q2 2013. Kenneth C. Frazier, Chairman and CEO of Merck, commented, "With seven of our top 10 products growing in the second quarter and solid performance overall, we continue to navigate significant patent expiries and adapt to the evolving global healthcare environment." Frazier added, "We remain committed to pursuing innovative, best-in-class science that translates into medically important products, such as our PD-1 inhibitor for oncology. To enable further investment in promising growth opportunities, we continue to manage costs effectively, as reflected in our results for the quarter." The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-02/MRK]

--

Bristol-Myers Squibb Company Research Report

On July 29, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb) announced that it has entered into a 10-year agreement with Samsung BioLogics (SBL), under which SBL will manufacture a commercial antibody cancer drug for Bristol-Myers Squibb at its recently completed plant in Songdo Incheon, South Korea. Louis Schmukler, President of Global Manufacturing & Supply at Bristol-Myers Squibb, commented, "This agreement increases our biologic manufacturing capacity to help ensure sufficient long-term supply of our commercial products." The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-02/BMY]

--

Eli Lilly and Company Research Report

On July 31, 2013, Eli Lilly and Company (Lilly) and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) together announced the enrollment of the first patient into a cardiovascular (CV) and renal outcomes trial for linagliptin (TRADJENTA) tablets. According to the Companies, CARMELINA1 (CArdiovascular Safety & Renal Microvascular outcomE study with LINAgliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk) trial will investigate the effect of the once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin on cardiovascular and renal outcomes in adults with type 2 diabetes (T2D) at risk of major macro- and microvascular events. Christophe Arbet-Engels, MD, PhD, Vice President of Metabolic-Clinical Development and Medical Affairs at BIPI, said, "Boehringer Ingelheim and Lilly are committed to patient safety, and we are pleased the first patient has been enrolled in the CARMELINA trial." Arbet-Engels continued, "Clinical trials like CARMELINA provide physicians with information they need to better understand the safety and efficacy of linagliptin, so that they can appropriately treat people with uncontrolled T2D."

The Full Research Report on Eli Lilly and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-02/LLY]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

http://www.InvestorsReports.com

SOURCE Investors' Reports